Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Acute Ischemic Stroke Therapeutics Report 2016: Pipeline Review of 17 Companies & 27 drug Molecules - Research and Markets

Research and Markets
Posted on: 28 Oct 16

Research and Markets has announced the addition of the "Acute Ischemic Stroke - Pipeline Review, H2 2016" report to their offering.

Acute Ischemic Stroke pipeline therapeutics constitutes close to 27 molecules. Out of which approximately 27 molecules are developed by Companies. Our latest report Acute Ischemic Stroke - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Acute Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Acute Ischemic Stroke Acute ischemic stroke is caused by a blockage in a blood vessel that stops the blood flow. The surrounding brain tissue becomes deprived of oxygen. Symptoms of acute ischemic stroke include loss of sensation and weakness in an arm, leg or one side of the body, partial loss of vision or hearing, slurred speech, double vision and dizziness. The predisposing factors include age, race, high blood pressure, diabetes mellitus, tobacco smoking, obesity, obstructive sleep apnea and dyslipidemia. The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 9, 5, 1 and 9 respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Acute Ischemic Stroke and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Acute Ischemic Stroke Overview
  3. Therapeutics Development
  4. Pipeline Products for Acute Ischemic Stroke - Overview
  5. Pipeline Products for Acute Ischemic Stroke - Comparative Analysis
  6. Acute Ischemic Stroke - Therapeutics under Development by Companies
  7. Acute Ischemic Stroke - Therapeutics under Investigation by Universities/Institutes
  8. Acute Ischemic Stroke Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Acute Ischemic Stroke - Products under Development by Companies
  13. Acute Ischemic Stroke - Products under Investigation by Universities/Institutes
  14. Acute Ischemic Stroke - Companies Involved in Therapeutics Development
  • AB Science SA
  • AstraZeneca Plc
  • Biogen Inc
  • D-Pharm Ltd.
  • Daiichi Sankyo Company, Limited
  • DiaMedica Inc.
  • Digna Biotech, S.L.
  • Glucox Biotech AB
  • Jeil Pharmaceutical Co., Ltd.
  • Lumosa Therapeutics Co., Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Pharmicell Co., Ltd.
  • PhytoHealth Corporation
  • Remedy Pharmaceuticals, Inc.
  • Saneron CCEL Therapeutics, Inc.
  • Simcere Pharmaceutical Group
  • Stemedica Cell Technologies, Inc.

For more information about this report visit

View source version on

Business Wire

Last updated on: 28/10/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.